Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

L20_2020_Cell_181_905_OA.pdf (4.11 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2020-04-24

Llicència de publicació

cc-by-nc-nd (c) Elsevier, 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/165519

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.cell.2020.04.004

Resum

We have previously provided the first genetic evidence that angiotensin converting enzyme 2 (ACE2) is the critical receptor for severe acute respiratory syndrome coronavirus (SARS-CoV), and ACE2 protects the lung from injury, providing a molecular explanation for the severe lung failure and death due to SARS-CoV infections. ACE2 has now also been identified as a key receptor for SARS-CoV-2 infections, and it has been proposed that inhibiting this interaction might be used in treating patients with COVID-19. However, it is not known whether human recombinant soluble ACE2 (hrsACE2) blocks growth of SARS-CoV-2. Here, we show that clinical grade hrsACE2 reduced SARS-CoV-2 recovery from Vero cells by a factor of 1,000-5,000. An equivalent mouse rsACE2 had no effect. We also show that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney organoids, which can be inhibited by hrsACE2. These data demonstrate that hrsACE2 can significantly block early stages of SARS-CoV-2 infections.

Matèries

Coronavirus, SARS-CoV-2, Terapèutica

Matèries (anglès)

Coronaviruses, SARS-CoV-2, Therapeutics

Citació

Col·leccions

Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))
Publicacions de projectes de recerca finançats per la UE

Citació

MONTEIL, Vanessa, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020. Vol. 181, num. 4, pags. 905-913. [consulted: 19 of August of 2026]. Available at: https://hdl.handle.net/2445/165519

Exportar metadades

JSON - METS

Compartir registre